文献速递慢性肾脏病肾血管病与高血压

螺内酯、依普利酮与非奈利酮在 cardiorenal 疾病谱中的应用时机

When to use spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases.
PubMed 文献 · Nephrol Dial Transplant · 2024-01-01

本文综述了甾体类盐皮质激素受体拮抗剂螺内酯和依普利酮在射血分数降低的心力衰竭或心肌梗死后患者中的疗效证据,以及非甾体类 MRA 非奈利酮在糖尿病肾脏病中的指南推荐地位。作者指出这些药物在不同患者群体中开发,尚未在整个 cardiorenal 疾病谱中全面验证,并梳理了未来研究方向。

要点

  • 螺内酯和依普利酮在 HFrEF 或心梗后改善结局,但在 CKD 患者中价值有限。
  • 非奈利酮已成为糖尿病肾脏病的指南推荐基础治疗。
  • 三类 MRA 尚未在整个 cardiorenal 疾病谱中全面验证,证据待补充。

核心结论

  • 螺内酯、依普利酮和非奈利酮因药理特征不同,需进一步考虑其在不同 cardiorenal 疾病场景中的定位。
  • 现有证据基础正通过正在进行的试验加以补充。

研究设计与样本

  • 综述,旨在综合现有证据并规划螺内酯、依普利酮和非奈利酮在 cardiorenal 疾病谱中的应用方向。

主要发现

  • 螺内酯和依普利酮在射血分数降低的心力衰竭或心肌梗死后改善患者结局,但在慢性肾脏病患者中价值有限。
  • 非奈利酮已成为糖尿病肾脏病患者指南推荐的基础治疗。
  • 这些药物在不同患者群体中开发,尚未在整个 cardiorenal 场景中接受测试。

临床怎么用

  • 在 cardiorenal 疾病谱中选用 MRA 时,需结合药物药理特征与现有证据人群进行决策。

局限性

  • 这些药物未在整个 cardiorenal 场景中全面验证,证据基础仍在补充中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Kidney disease frequently coexists with cardiovascular (CV) diseases, and this dual presence significantly amplifies the risk of adverse clinical outcomes. Shared pathophysiological mechanisms and common CV risk factors contribute to the increased expression of mineralocorticoid receptors, which in turn can drive the progression of chronic CV-kidney disorders. The steroidal mineralocorticoid receptor antagonists (MRAs) spironolactone and eplerenone have demonstrated efficacy in improving patient outcomes in cases of heart failure with reduced ejection fraction or after a myocardial infarction, but have limited value in patients with chronic kidney disease. The non-steroidal MRA finerenone has now established itself as a foundational guideline-recommended therapy in patients with diabetic kidney disease. To date, these pharmacological agents have been developed in distinct patient populations. The consequences of their distinct pharmacological profiles necessitate further consideration. They have not undergone testing across the entire spectrum of cardiorenal scenarios, and the evidence base is currently being complemented with ongoing trials. In this review, we aim to synthesize the existing body of evidence and chart the future trajectory for the use of spironolactone, eplerenone and finerenone in improving clinical outcomes across the diverse spectrum of cardiorenal diseases. By consolidating the current state of knowledge, we seek to provide valuable insights for informed decision making in the management of patients with these complex and interconnected conditions.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Kobayashi M, Girerd N, Zannad F, et al. When to use spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases. Nephrol Dial Transplant. 2024. PMID: 38192033. doi:10.1093/ndt/gfae004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。